Spine

Safe Orthopaedics Acquires a Direct Sales Force in the United Kingdom

June 01, 2018

ERAGNY-SUR-OISE, France–(BUSINESS WIRE)–Regulatory News:

SAFE ORTHOPAEDICS (FR0012452746 – SAFOR) (Paris:SAFOR), a company specialising in the design and marketing of single-use implants and instruments facilitating the minimally invasive treatment of spinal fracture conditions, is today announcing a deal to acquire the sales force of UK company Qspine, which specialises in distributing medical equipment for spinal surgery.

Since 2014, Qspine has distributed Safe Orthopaedics in the UK. The UK is Europe’s second largest market for spinal fusion surgery, worth an estimated €105 million, including €12 million for spinal fracture conditions alone.

“With the confidence resulting from our growing market share in France and initial positive signs in Germany, we are extending our direct distribution network in Europe by acquiring the sales force of our long-standing UK distributor. This sales force consists of four experienced salespeople and has delivered solid adoption of our technology with limited resources. We will gradually increase commercial resources and marketing efforts in the UK, and we intend to realise the full potential of our technology in the UK market with the medium-term aim of matching our current market share in France. These sales will contribute to the growth of the group as of the second semester of 2018,” said Pierre Dumouchel, CEO and co-founder of Safe Orthopaedics. “By selling our SteriSpine technologies directly to hospitals, we will improve our overall gross margin while also becoming more competitive and more flexible in terms of our selling prices. We are also very interested in promoting Qspine’s single-use illuminated retractor technology, which will be an excellent fit with our range.”

Qspine’s SURE retractor has recently obtained the CE mark and is now commercially available. The SURE system consists of a single-use, sterile radiolucent retractor, offering surgeons a genuine alternative – in both technical and economic terms – to traditional reusable products, while also offering a novel integrated illumination option. Safe Orthopaedics become the sole distributor of the SURE system in France, and will promote it in the UK.

“I believe this collaboration will benefit both companies. It will allow Safe Orthopaedics to quicken the pace in the UK market and gain quick access to accounts by using the unique SURE retractor. I look forward to working closely with Safe Orthopaedics to allow more surgeons to experience the many benefits that SteriSpine and SURE can deliver,” added Alan Lawson, CEO of Qspine.

Forthcoming financial events:

  • General Shareholders’ Meeting, Thursday June 28, 2018
  • Second-quarter 2018 revenues: July 10, 2018 (after the market close)

About Safe Orthopaedics

Founded in 2010, Safe Orthopaedics is a French medical technology company that offers the safest technologies to treat spinal fracture. Delivered sterile, all implants and respective disposable instrumentation are available to the surgeon at any time, any place. These technologies enable minimally invasive approaches, reducing risks of cross contamination and infection in the interest of the patient. Protected by 17 patent families, the SteriSpine™ Kits are CE marked and FDA cleared. The company is based at Eragny-Sur-Oise (France), and has 37 employees.

For more information, visit: www.SafeOrtho.com

About the SURE retractor

For more information, visit: www.suresystem.com

Contacts

Safe Orthopaedics
François-Henri Reynaud, +33 (0)1 34 21 50 00
CFO
investors@safeorthopaedics.com
or
Investor Relations
NewCap
Julien Perez / Valentine Brouchot
+33 (0)1 44 71 94 94
SafeOrtho@newcap.eu
or
Press Relations
Ulysse Communication
Bruno Arabian, 06 87 88 47 26
barabian@ulysse-communication.com
or
Nicolas Daniels, 06 63 66 59 22
ndaniels@ulysse-communication.com

Related Articles

Back to top button